March 15, 2025

clinical trials

Home clinical trials
Investors

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

  • May 19, 2024

Dyne Therapeutics, Inc. WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials

Read More
Finance

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

  • May 1, 2024

Tevogen Bio Inc Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a

Read More
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent. View more
Accept
Decline